JP5382952B2 - 糖尿病の治療のためのオキサジアゾアントラセン化合物 - Google Patents
糖尿病の治療のためのオキサジアゾアントラセン化合物 Download PDFInfo
- Publication number
- JP5382952B2 JP5382952B2 JP2010549910A JP2010549910A JP5382952B2 JP 5382952 B2 JP5382952 B2 JP 5382952B2 JP 2010549910 A JP2010549910 A JP 2010549910A JP 2010549910 A JP2010549910 A JP 2010549910A JP 5382952 B2 JP5382952 B2 JP 5382952B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- oxo
- diaza
- hexahydro
- oxa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(*)N(*)C(C(Cc1c2)N(*)Cc1cc(OC1*)c2N(*)C1=O)=O Chemical compound *C(*)N(*)C(C(Cc1c2)N(*)Cc1cc(OC1*)c2N(*)C1=O)=O 0.000 description 5
- VQFUQWSLCGKJHB-LLNQOWJMSA-N CC(C)(C)OC(N(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2NC3=O)C1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O)=O Chemical compound CC(C)(C)OC(N(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2NC3=O)C1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O)=O VQFUQWSLCGKJHB-LLNQOWJMSA-N 0.000 description 1
- WPZBDQDSVIYYQE-PXWFVKLRSA-N CC(C)C(CC[C@@H](C)C1)[C@@H]1OC(C(Cc1c2)NCc1cc(O[C@@H]1c(cc3)ccc3OCc(cc3Cl)ccc3Cl)c2N(C)C1=O)=O Chemical compound CC(C)C(CC[C@@H](C)C1)[C@@H]1OC(C(Cc1c2)NCc1cc(O[C@@H]1c(cc3)ccc3OCc(cc3Cl)ccc3Cl)c2N(C)C1=O)=O WPZBDQDSVIYYQE-PXWFVKLRSA-N 0.000 description 1
- DXDOGYTXQVLEDW-FZIDKRJVSA-N CC(C)c1c(CN(Cc(c(C2)c3)cc(OC4c(cc5)ccc5OCc(cc5Cl)ccc5Cl)c3N(C)C4=O)C2C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)C(O)=O)=O)cccc1 Chemical compound CC(C)c1c(CN(Cc(c(C2)c3)cc(OC4c(cc5)ccc5OCc(cc5Cl)ccc5Cl)c3N(C)C4=O)C2C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)C(O)=O)=O)cccc1 DXDOGYTXQVLEDW-FZIDKRJVSA-N 0.000 description 1
- UQYVUBICGBEPLT-OOICUZEHSA-N CCC(c1ccccc1)N(Cc(c(C1)c2)cc(O[C@@H]3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2N(C)C3=O)C1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(OC)=O)=O Chemical compound CCC(c1ccccc1)N(Cc(c(C1)c2)cc(O[C@@H]3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2N(C)C3=O)C1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(OC)=O)=O UQYVUBICGBEPLT-OOICUZEHSA-N 0.000 description 1
- QQDMVOWSULYZTD-HFGJLVPKSA-N CC[C@@H](c1ccccc1)N(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2N(C)C3=O)[C@@H]1C(N[C@@](C)(Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O Chemical compound CC[C@@H](c1ccccc1)N(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2N(C)C3=O)[C@@H]1C(N[C@@](C)(Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O QQDMVOWSULYZTD-HFGJLVPKSA-N 0.000 description 1
- ZXJQFMYVTDGFTB-WWAORTSFSA-N CC[C@@H](c1ccccc1)N(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4Cl)ccc4Cl)c2N(C)C3=O)[C@@H]1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O Chemical compound CC[C@@H](c1ccccc1)N(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4Cl)ccc4Cl)c2N(C)C3=O)[C@@H]1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O ZXJQFMYVTDGFTB-WWAORTSFSA-N 0.000 description 1
- AGPUINSRNKXTIU-JWLVZHBKSA-N CN1c(cc(CC(C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)C(O)=O)=O)N(CC2(CCCC2)c2ccccc2)C2)c2c2)c2OC(c(cc2)ccc2OCc(cc2Cl)ccc2Cl)C1=O Chemical compound CN1c(cc(CC(C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)C(O)=O)=O)N(CC2(CCCC2)c2ccccc2)C2)c2c2)c2OC(c(cc2)ccc2OCc(cc2Cl)ccc2Cl)C1=O AGPUINSRNKXTIU-JWLVZHBKSA-N 0.000 description 1
- YKJKZJCVIAUGMO-VOOFDKNSSA-N Cc1ccccc1CN(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2NC3=O)C1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O Chemical compound Cc1ccccc1CN(Cc(c(C1)c2)cc(OC3c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c2NC3=O)C1C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O YKJKZJCVIAUGMO-VOOFDKNSSA-N 0.000 description 1
- KKOKPMHWXQRCPJ-SYVAAPJHSA-N Cc1nc(CN(Cc(c(C2)c3)cc(OC4c(cc5)ccc5OCc(cc5Cl)ccc5Cl)c3NC4=O)C2C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)C(O)=O)=O)ccc1 Chemical compound Cc1nc(CN(Cc(c(C2)c3)cc(OC4c(cc5)ccc5OCc(cc5Cl)ccc5Cl)c3NC4=O)C2C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)C(O)=O)=O)ccc1 KKOKPMHWXQRCPJ-SYVAAPJHSA-N 0.000 description 1
- WDTULTZQNLWSEA-PMFORLRSSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc(cc3)Cl)c3Cl)C4=O)N2C(c2ccccc2)=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc(cc3)Cl)c3Cl)C4=O)N2C(c2ccccc2)=O)=O)cc1 WDTULTZQNLWSEA-PMFORLRSSA-N 0.000 description 1
- GCDDSNQSDDTDTE-CWYXMSDZSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(OC2CCOCC2)=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(OC2CCOCC2)=O)=O)cc1 GCDDSNQSDDTDTE-CWYXMSDZSA-N 0.000 description 1
- OCWQIIPVLBQVEG-BGLVMXALSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(OCC2CC2)=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(OCC2CC2)=O)=O)cc1 OCWQIIPVLBQVEG-BGLVMXALSA-N 0.000 description 1
- LMKQATDQANPVME-BJLGZMSWSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3Cl)ccc3Cl)C4=O)N2S(c(cccc2)c2[N+]([O-])=O)(=O)=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3Cl)ccc3Cl)C4=O)N2S(c(cccc2)c2[N+]([O-])=O)(=O)=O)=O)cc1 LMKQATDQANPVME-BJLGZMSWSA-N 0.000 description 1
- SIOLMVPINQYTKK-VOOFDKNSSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc4ccccc4C#N)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc4ccccc4C#N)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 SIOLMVPINQYTKK-VOOFDKNSSA-N 0.000 description 1
- WWEDIOLJVSBYRU-PMFORLRSSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc4ccccn4)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc4ccccn4)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 WWEDIOLJVSBYRU-PMFORLRSSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3459908P | 2008-03-07 | 2008-03-07 | |
| US61/034,599 | 2008-03-07 | ||
| PCT/US2009/036333 WO2009111700A2 (en) | 2008-03-07 | 2009-03-06 | Oxadiazoanthracene compounds for the treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513431A JP2011513431A (ja) | 2011-04-28 |
| JP2011513431A5 JP2011513431A5 (https=) | 2013-02-14 |
| JP5382952B2 true JP5382952B2 (ja) | 2014-01-08 |
Family
ID=41056666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549910A Active JP5382952B2 (ja) | 2008-03-07 | 2009-03-06 | 糖尿病の治療のためのオキサジアゾアントラセン化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7727983B2 (https=) |
| EP (1) | EP2262364B1 (https=) |
| JP (1) | JP5382952B2 (https=) |
| KR (1) | KR101616737B1 (https=) |
| CN (1) | CN101959405B (https=) |
| AU (1) | AU2009221722B2 (https=) |
| BR (1) | BRPI0910282A2 (https=) |
| CA (1) | CA2716664C (https=) |
| DK (1) | DK2262364T3 (https=) |
| EA (1) | EA018225B1 (https=) |
| ES (1) | ES2567451T3 (https=) |
| IL (1) | IL207570A (https=) |
| MA (1) | MA32175B1 (https=) |
| MX (1) | MX2010009752A (https=) |
| NZ (1) | NZ587343A (https=) |
| WO (1) | WO2009111700A2 (https=) |
| ZA (1) | ZA201006367B (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| CN102378574B (zh) | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| NZ611529A (en) | 2010-12-23 | 2015-06-26 | Pfizer | Glucagon receptor modulators |
| WO2012096824A1 (en) * | 2011-01-12 | 2012-07-19 | Transtech Pharma, Inc. | Phenylglyoxylic acid derivatives and their preparation and use |
| WO2012107850A1 (en) | 2011-02-08 | 2012-08-16 | Pfizer Inc. | Glucagon receptor modulator |
| US8927577B2 (en) | 2011-07-22 | 2015-01-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EA201491749A1 (ru) | 2012-03-22 | 2015-01-30 | ТРАНСТЕК ФАРМА, ЭлЭлСи | Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение |
| US20150297573A1 (en) | 2012-10-24 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL |
| AU2014207748B2 (en) * | 2013-01-17 | 2018-10-11 | Vtv Therapeutics Llc | Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
| CA2955836C (en) * | 2014-07-25 | 2023-02-14 | Celgene International Ii Sarl | Glp-1 receptor modulators |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| TW201925204A (zh) * | 2017-11-22 | 2019-07-01 | 日商第一三共股份有限公司 | 稠合三環化合物 |
| MX2020008387A (es) | 2018-05-08 | 2020-12-11 | Vtv Therapeutics Llc | Usos terapeuticos de agonistas glp1r. |
| MA54555A (fr) | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12459954B2 (en) | 2020-04-01 | 2025-11-04 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Crystalline form a of GLP-1 receptor agonist and preparation method therefor |
| JP2023528726A (ja) | 2020-04-01 | 2023-07-06 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202210461A (zh) * | 2020-05-28 | 2022-03-16 | 中國大陸商杭州中美華東製藥有限公司 | 一種（ｓ）—２—胺基—３—（４—（２，３—二甲基吡啶—４—基）苯基）丙酸甲酯二酸鹽的製備方法 |
| EP4159737A4 (en) * | 2020-05-28 | 2024-10-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| CN116710446B (zh) | 2020-10-14 | 2024-10-18 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂的晶型及其用途 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| MX2023006186A (es) | 2020-11-27 | 2023-08-07 | Shenzhen Salubris Pharm Co Ltd | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. |
| US20240208952A1 (en) | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| JP7772778B2 (ja) | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| CN117500808B (zh) * | 2021-06-17 | 2026-03-06 | 杭州中美华东制药有限公司 | 蒽类化合物、其制备方法和医药用途 |
| IL309235A (en) | 2021-06-24 | 2024-02-01 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Glp-1 receptor agonist and composition and use thereof |
| CN115521320B (zh) * | 2021-06-25 | 2023-09-05 | 沈阳兴齐眼药股份有限公司 | 一种制备普拉洛芬的方法 |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6345270A (ja) * | 1986-02-11 | 1988-02-26 | Takeda Chem Ind Ltd | １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物 |
| EP0233728A1 (en) * | 1986-02-11 | 1987-08-26 | Takeda Chemical Industries, Ltd. | 1,4-Benzoxazine derivatives their production and use |
| WO1997012853A1 (en) * | 1995-10-06 | 1997-04-10 | Ligand Pharmaceuticals Incorporated | Dimer-selective rxr modulators and methods for their use |
| WO2000042026A1 (en) * | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| WO2001040192A1 (en) * | 1999-12-03 | 2001-06-07 | Kyoto Pharmaceutical Industries, Ltd. | Novel heterocyclic compounds and salts thereof and medicinal use of the same |
| EP1125925A1 (en) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US20050222036A1 (en) * | 2000-08-24 | 2005-10-06 | Thomas Jefferson University | Peptide compositions with effects on blood glucose |
| ES2327737T3 (es) * | 2003-03-26 | 2009-11-03 | Actelion Pharmaceuticals Ltd. | Derivados de tetrahidroisoquinolil acetamida para uso como antagonistas de receptores de orexina. |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| JP2013530963A (ja) | 2010-06-09 | 2013-08-01 | レセプトス インコーポレイテッド | 新規のｇｌｐ−１受容体安定化薬および調節薬 |
-
2009
- 2009-03-06 EA EA201071045A patent/EA018225B1/ru not_active IP Right Cessation
- 2009-03-06 CN CN200980108115.XA patent/CN101959405B/zh active Active
- 2009-03-06 BR BRPI0910282-5A patent/BRPI0910282A2/pt not_active Application Discontinuation
- 2009-03-06 US US12/399,504 patent/US7727983B2/en active Active
- 2009-03-06 CA CA2716664A patent/CA2716664C/en active Active
- 2009-03-06 WO PCT/US2009/036333 patent/WO2009111700A2/en not_active Ceased
- 2009-03-06 NZ NZ587343A patent/NZ587343A/en not_active IP Right Cessation
- 2009-03-06 DK DK09718287.7T patent/DK2262364T3/en active
- 2009-03-06 JP JP2010549910A patent/JP5382952B2/ja active Active
- 2009-03-06 ES ES09718287T patent/ES2567451T3/es active Active
- 2009-03-06 AU AU2009221722A patent/AU2009221722B2/en active Active
- 2009-03-06 MX MX2010009752A patent/MX2010009752A/es active IP Right Grant
- 2009-03-06 EP EP09718287.7A patent/EP2262364B1/en active Active
- 2009-03-06 KR KR1020107020688A patent/KR101616737B1/ko not_active Expired - Fee Related
-
2010
- 2010-04-13 US US12/759,010 patent/US7790714B2/en active Active
- 2010-08-03 US US12/849,225 patent/US7906507B2/en active Active
- 2010-08-12 IL IL207570A patent/IL207570A/en active IP Right Grant
- 2010-08-31 US US12/872,580 patent/US8524708B2/en not_active Expired - Fee Related
- 2010-09-10 ZA ZA2010/06367A patent/ZA201006367B/en unknown
- 2010-09-30 MA MA33212A patent/MA32175B1/fr unknown
-
2013
- 2013-08-01 US US13/956,578 patent/US8703766B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/197,771 patent/US8933222B2/en active Active
- 2014-12-01 US US14/556,837 patent/US9120813B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5382952B2 (ja) | 糖尿病の治療のためのオキサジアゾアントラセン化合物 | |
| JP5755217B2 (ja) | 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法 | |
| HK1148435B (en) | Oxadiazoanthracene compounds for the treatment of diabetes | |
| HK1164050B (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121211 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130925 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130926 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130930 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5382952 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |